In a report issued on July 22, Cory Kasimov from J.P. Morgan maintained a Hold rating on Biogen (BIIB), with a price target of $279.00. The company’s shares closed last Tuesday at $280.35.
According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 21.8% and a 57.0% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Alexion Pharmaceuticals, and BioMarin Pharmaceutical.
Currently, the analyst consensus on Biogen is a Moderate Buy with an average price target of $308.79, a 7.9% upside from current levels. In a report issued on July 8, Jefferies also maintained a Hold rating on the stock with a $320.00 price target.
See today’s analyst top recommended stocks >>
Biogen’s market cap is currently $44.38B and has a P/E ratio of 8.40. The company has a Price to Book ratio of 20.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Read More on BIIB: